Use and safety of denosumab in cancer patients.

Background Few data have been reported on the use and safety of denosumab in patients with solid tumors and bone metastasis in clinical practice. Objectives To describe the use of denosumab and to analyze its adverse effects (AE) in tertiary hospital cancer outpatients. Methods Retrospective study of patients who started denosumab between January 2013 and June 2015.

Desensitization to rituximab in a multidisciplinary setting.

Background: The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols.

Objective: To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme.

Method: Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab.

Level of adherence to an extravasation protocol over 10 years in a tertiary care hospital.

Background: Extravasation of chemotherapy is an undesirable complication related to the administration of antineoplastic therapy. Establishing the real incidence is difficult. Because of the importance of a quick intervention after an extravasation, every hospital should have an extravasation protocol.

Dosing of chemotherapy in obese and cachectic patients: results of a national survey.

Background: It is not unusual to find obese and cachectic patients in the hematology oncology setting. However, information on dosage in these groups is scarce.

Objective: The objectives of our study were to explore the dosing strategies applied in the treatment of obese and cachectic cancer patients and to determine whether these strategies are applied in clinical trials.

Prescribing of zoledronic acid in a tertiary outpatient hospital setting.

Background: Zoledronic acid (ZA) is an intravenous bisphosphonate approved for the prevention and treatment of cancer skeletal-related events.

Objective: Our aim was to analyze the prescription patterns of ZA in the cancer outpatient clinic.

Method: We performed a retrospective chart review of all patients who received at least 1 dose of ZA from January 2009 until December 2010 in our institution.